{"entity":{"id":"nct07450976","kind":"trial","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","aka":[],"tldr":"A phase 2 trial of SHR-A1904 for Injection in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer is a phase 2 interventional study registered as NCT07450976 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 151 participants planned, started 2026-03-25 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-A1904 for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07450976","url":"https://clinicaltrials.gov/study/NCT07450976"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07450976","phase":"2","setting":"A Phase IIa/IIb Clinical Study of SHR-A1904 in Patients With Previous Systemic Treatment Failure, Positive CLDN18.2 Expression of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":151,"outcomes":[]},"route":"/trials/nct07450976/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}